


REMARKS

Currently claims 1-10 are pending. Claims 1-2, 5-6, and 9-10 are cancelled herein. Claims 11-26 are newly introduced. Accordingly, claims 3-4, 7-8, and 11-26 are presented for examination. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,

  
John L. Lemanowicz  
Attorney for Applicant  
Registration No. 37,360

Date: November 5, 2006  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-8247  
Facsimile: 919-483-7988